Noroxycodone	oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	53	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	45	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	45	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	48	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		none	7804	none	D010098
Noroxycodone	oxycodone	46	48	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		none	7804	none	D010098
Noroxycodone	creatinine	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	none	none	none
Noroxycodone	Oxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	53	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	45	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	45	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	48	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		none	7804	none	D010098
Noroxycodone	Oxycodone	46	48	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		none	7804	none	D010098
Noroxycodone	gh	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	none	none	none
Noroxycodone	gh	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	gh	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	noroxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	noroxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	noroxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	none	none	none
Noroxycodone	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
Noroxycodone	noroxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		none	none	none	none
Noroxycodone	noroxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
Noroxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
Noroxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
Noroxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
Noroxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
Noroxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	none	none	none
Noroxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Noroxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
Noroxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
Noroxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Noroxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
Noroxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
Noroxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	none	none	none
Noroxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Noroxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Noroxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Thyroid stimulating hormone	glucagon	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	4832	D013972	D005934
Thyroid stimulating hormone	glucagon	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	4832	D013972	D005934
Thyroid stimulating hormone	gh	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	none
Thyroid stimulating hormone	gh	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	none
Thyroid stimulating hormone	prolactin	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	1426890	D013972	D011388
Thyroid stimulating hormone	prolactin	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	1426890	D013972	D011388
Thyroid stimulating hormone	lh	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	none
Thyroid stimulating hormone	lh	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	none
Thyroid stimulating hormone	cortisol	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	5492	D013972	D006854
Thyroid stimulating hormone	cortisol	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	5492	D013972	D006854
Thyroid stimulating hormone	growth hormone	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	D013006
Thyroid stimulating hormone	growth hormone	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	none	D013972	D013006
Thyroid stimulating hormone	luteinizing hormone	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	6383	D013972	6383
Thyroid stimulating hormone	luteinizing hormone	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	6383	D013972	6383
Thyroid stimulating hormone	ACTH	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	376	D013972	D000324
Thyroid stimulating hormone	ACTH	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	376	D013972	D000324
Thyroid stimulating hormone	insulin	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	5856	D013972	D007328
Thyroid stimulating hormone	insulin	23	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.  		10579	5856	D013972	D007328
glucagon	gh	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	none
glucagon	gh	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	none
glucagon	prolactin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	1426890	D005934	D011388
glucagon	prolactin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	1426890	D005934	D011388
glucagon	lh	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	none
glucagon	lh	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	none
glucagon	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	5492	D005934	D006854
glucagon	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	5492	D005934	D006854
glucagon	growth hormone	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	D013006
glucagon	growth hormone	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	none	D005934	D013006
glucagon	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	6383	D005934	6383
glucagon	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	6383	D005934	6383
glucagon	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	376	D005934	D000324
glucagon	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	376	D005934	D000324
glucagon	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	5856	D005934	D007328
glucagon	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		4832	5856	D005934	D007328
oxycodone hydrochloride	oxycodone	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	oxycodone	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	oxycodone	16	18	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone hydrochloride	oxycodone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
oxycodone hydrochloride	oxycodone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	oxycodone	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	oxycodone	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	oxycodone	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	oxycodone	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	5	7	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone hydrochloride	oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone hydrochloride	oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	oxycodone	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	8	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	9	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	oxycodone	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	oxycodone	26	27	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone hydrochloride	oxycodone	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
oxycodone hydrochloride	oxycodone	26	28	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone hydrochloride	oxycodone	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	oxycodone	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	oxycodone	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
oxycodone hydrochloride	oxycodone	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	amylase	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		7804	743	D010098	D000681
oxycodone hydrochloride	amylase	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		7804	743	D010098	D000681
oxycodone hydrochloride	amylase	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		7804	743	D010098	D000681
oxycodone hydrochloride	amylase	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		7804	743	D010098	D000681
oxycodone hydrochloride	Oxycodone	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	16	18	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	5	7	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	8	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	9	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	26	27	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	26	28	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
oxycodone hydrochloride	Oxycodone	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
oxycodone hydrochloride	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
oxycodone hydrochloride	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
oxycodone hydrochloride	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
oxycodone hydrochloride	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
oxycodone hydrochloride	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
oxycodone hydrochloride	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone hydrochloride	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone hydrochloride	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone hydrochloride	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
oxycodone hydrochloride	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
oxycodone hydrochloride	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone hydrochloride	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone hydrochloride	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
oxycodone hydrochloride	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
oxycodone hydrochloride	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone hydrochloride	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone hydrochloride	Oxycodone hydrochloride	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone hydrochloride	Oxycodone hydrochloride	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
oxycodone hydrochloride	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone hydrochloride	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone hydrochloride	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone hydrochloride	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone	amylase	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		7804	743	D010098	D000681
oxycodone	amylase	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		7804	743	D010098	D000681
oxycodone	amylase	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		7804	743	D010098	D000681
oxycodone	amylase	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		7804	743	D010098	D000681
oxycodone	creatinine	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	creatinine	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	creatinine	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	creatinine	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
oxycodone	creatinine	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
oxycodone	Oxycodone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
oxycodone	Oxycodone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone	5	7	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone	6	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone	6	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone	6	7	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone	6	8	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone	7	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone	7	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone	7	7	true	positive	Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone	7	8	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone	7	9	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone	8	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone	9	7	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
oxycodone	Oxycodone	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone	16	18	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone	Oxycodone	18	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone	Oxycodone	18	18	false	none	Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone	Oxycodone	27	27	false	none	The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone	Oxycodone	27	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone	Oxycodone	27	29	false	none	The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  The apparent elimination half-life of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	27	28	false	none	The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone	26	27	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone	Oxycodone	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
oxycodone	Oxycodone	26	28	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone	29	27	false	none	The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  The apparent elimination half-life of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	29	29	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	29	28	false	none	Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  The apparent elimination half-life of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	29	31	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	28	27	false	none	The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone	28	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone	28	29	false	none	Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  The apparent elimination half-life of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	28	28	false	none	Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone	31	29	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	31	31	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	34	34	true	positive	Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  		D010098	D010098
oxycodone	Oxycodone	34	35	true	positive	Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  		D010098	D010098
oxycodone	Oxycodone	34	36	true	positive	Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  		D010098	D010098
oxycodone	Oxycodone	35	34	true	positive	Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  		D010098	D010098
oxycodone	Oxycodone	35	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  		D010098	D010098
oxycodone	Oxycodone	35	36	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  		D010098	D010098
oxycodone	Oxycodone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone	38	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	36	34	true	positive	Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  		D010098	D010098
oxycodone	Oxycodone	36	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  		D010098	D010098
oxycodone	Oxycodone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone	36	36	false	none	Oxycodone has been found in breast milk.  		D010098	D010098
oxycodone	Oxycodone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone	37	35	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone	37	36	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone	43	43	true	positive	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		D010098	D010098
oxycodone	Oxycodone	43	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		D010098	D010098
oxycodone	Oxycodone	43	45	true	positive	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		D010098	D010098
oxycodone	Oxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		D010098	D010098
oxycodone	Oxycodone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		D010098	D010098
oxycodone	Oxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		D010098	D010098
oxycodone	Oxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		D010098	D010098
oxycodone	Oxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		D010098	D010098
oxycodone	Oxycodone	46	45	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		D010098	D010098
oxycodone	Oxycodone	46	48	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	45	43	true	positive	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		D010098	D010098
oxycodone	Oxycodone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		D010098	D010098
oxycodone	Oxycodone	45	45	true	positive	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		D010098	D010098
oxycodone	Oxycodone	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		D010098	D010098
oxycodone	Oxycodone	51	50	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		D010098	D010098
oxycodone	Oxycodone	51	49	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		D010098	D010098
oxycodone	Oxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		D010098	D010098
oxycodone	Oxycodone	51	52	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		D010098	D010098
oxycodone	Oxycodone	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		D010098	D010098
oxycodone	Oxycodone	50	50	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	50	49	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	50	48	false	none	Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	50	52	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		D010098	D010098
oxycodone	Oxycodone	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		D010098	D010098
oxycodone	Oxycodone	49	50	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	49	49	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  		D010098	D010098
oxycodone	Oxycodone	49	48	false	none	Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  		D010098	D010098
oxycodone	Oxycodone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	48	50	false	none	Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  		D010098	D010098
oxycodone	Oxycodone	48	49	false	none	Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  		D010098	D010098
oxycodone	Oxycodone	48	48	false	none	Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		D010098	D010098
oxycodone	Oxycodone	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		D010098	D010098
oxycodone	Oxycodone	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		D010098	D010098
oxycodone	Oxycodone	55	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		D010098	D010098
oxycodone	Oxycodone	55	56	false	none	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		D010098	D010098
oxycodone	Oxycodone	54	55	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		D010098	D010098
oxycodone	Oxycodone	54	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		D010098	D010098
oxycodone	Oxycodone	54	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		D010098	D010098
oxycodone	Oxycodone	54	52	true	positive	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		D010098	D010098
oxycodone	Oxycodone	54	56	false	none	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		D010098	D010098
oxycodone	Oxycodone	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		D010098	D010098
oxycodone	Oxycodone	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		D010098	D010098
oxycodone	Oxycodone	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		D010098	D010098
oxycodone	Oxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		D010098	D010098
oxycodone	Oxycodone	53	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		D010098	D010098
oxycodone	Oxycodone	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		D010098	D010098
oxycodone	Oxycodone	52	50	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		D010098	D010098
oxycodone	Oxycodone	52	54	true	positive	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		D010098	D010098
oxycodone	Oxycodone	52	53	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		D010098	D010098
oxycodone	Oxycodone	52	52	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		D010098	D010098
oxycodone	Oxycodone	56	55	false	none	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		D010098	D010098
oxycodone	Oxycodone	56	54	false	none	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		D010098	D010098
oxycodone	Oxycodone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		D010098	D010098
oxycodone	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
oxycodone	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
oxycodone	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
oxycodone	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
oxycodone	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
oxycodone	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
oxycodone	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
oxycodone	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
oxycodone	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
oxycodone	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	6	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	6	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
oxycodone	gh	7	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		7804	none	D010098	none
oxycodone	gh	7	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		7804	none	D010098	none
oxycodone	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
oxycodone	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
oxycodone	gh	29	31	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
oxycodone	gh	29	31	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
oxycodone	gh	31	32	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  		7804	none	D010098	none
oxycodone	gh	31	32	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  		7804	none	D010098	none
oxycodone	gh	31	31	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
oxycodone	gh	31	31	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
oxycodone	gh	34	32	true	positive	Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  Food caused a delay in Tmax (1.00 to 3.00 hours).  Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  		7804	none	D010098	none
oxycodone	gh	34	32	true	positive	Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  Food caused a delay in Tmax (1.00 to 3.00 hours).  Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  		7804	none	D010098	none
oxycodone	gh	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	gh	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	gh	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	gh	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	gh	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	gh	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	gh	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
oxycodone	gh	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	gh	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	gh	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
oxycodone	gh	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
oxycodone	noroxycodone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	noroxycodone	43	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	noroxycodone	43	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	noroxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
oxycodone	noroxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	noroxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	noroxycodone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	noroxycodone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	noroxycodone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	noroxycodone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	noroxycodone	55	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	noroxycodone	55	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	noroxycodone	54	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	noroxycodone	54	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	noroxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	noroxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	noroxycodone	52	53	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	noroxycodone	52	53	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
oxycodone	Oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	Oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	Oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
oxycodone	Oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
oxycodone	Oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	Oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	Oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	Oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	Oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	p450	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	rifampin	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	54	55	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	54	55	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
oxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
oxycodone	oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
oxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
oxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
oxycodone	oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
oxycodone	oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
oxycodone	oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
oxycodone	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	54	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	54	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	52	54	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	52	54	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
oxycodone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
oxycodone	Oxycodone hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	6	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	6	8	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	7	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	7	8	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	7	9	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	18	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	27	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	28	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
oxycodone	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
oxycodone	histamine	18	17	false	none	Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		7804	5333	D010098	D006632
oxycodone	histamine	18	17	false	none	Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		7804	5333	D010098	D006632
amylase	Oxycodone	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		743	7804	D000681	D010098
amylase	Oxycodone	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		743	7804	D000681	D010098
amylase	Oxycodone	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		743	7804	D000681	D010098
amylase	Oxycodone	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		743	7804	D000681	D010098
amylase	Oxycodone hydrochloride	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		743	7804	D000681	D010098
amylase	Oxycodone hydrochloride	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		743	7804	D000681	D010098
amylase	Oxycodone hydrochloride	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		743	7804	D000681	D010098
amylase	Oxycodone hydrochloride	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		743	7804	D000681	D010098
amylase	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		743	5333	D000681	D006632
amylase	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		743	5333	D000681	D006632
creatinine	Oxycodone	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	50	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	50	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	49	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	49	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	7804	none	D010098
creatinine	Oxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
creatinine	Oxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	7804	none	D010098
creatinine	Oxycodone	51	52	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		none	7804	none	D010098
creatinine	Oxycodone	51	52	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		none	7804	none	D010098
creatinine	gh	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		none	none	none	none
creatinine	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	none	none	none
Oxycodone	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
Oxycodone	gh	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		7804	none	D010098	none
Oxycodone	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
Oxycodone	gh	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		7804	none	D010098	none
Oxycodone	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
Oxycodone	gh	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		7804	none	D010098	none
Oxycodone	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		7804	none	D010098	none
Oxycodone	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	4	6	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
Oxycodone	gh	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		7804	none	D010098	none
Oxycodone	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	5	6	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	6	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	6	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		7804	none	D010098	none
Oxycodone	gh	7	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		7804	none	D010098	none
Oxycodone	gh	7	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		7804	none	D010098	none
Oxycodone	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
Oxycodone	gh	8	6	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		7804	none	D010098	none
Oxycodone	gh	29	31	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
Oxycodone	gh	29	31	false	none	The apparent elimination half-life of oxycodone is approximately 4 hours.  Absorption  About 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose.  This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
Oxycodone	gh	31	32	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  		7804	none	D010098	none
Oxycodone	gh	31	32	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  		7804	none	D010098	none
Oxycodone	gh	31	31	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
Oxycodone	gh	31	31	false	none	This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone.  		7804	none	D010098	none
Oxycodone	gh	34	32	true	positive	Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  Food caused a delay in Tmax (1.00 to 3.00 hours).  Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  		7804	none	D010098	none
Oxycodone	gh	34	32	true	positive	Food Effects  When administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%.  Food caused a delay in Tmax (1.00 to 3.00 hours).  Distribution  Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  		7804	none	D010098	none
Oxycodone	gh	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	gh	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	gh	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	gh	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	gh	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	gh	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	gh	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	51	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	50	51	false	none	Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	49	51	false	none	Special Populations    Elderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.  Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone.  Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  		7804	none	D010098	none
Oxycodone	gh	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	gh	53	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	gh	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
Oxycodone	gh	52	51	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  		7804	none	D010098	none
Oxycodone	noroxycodone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	38	40	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	noroxycodone	43	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	noroxycodone	43	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	40	41	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	41	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	41	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  		7804	none	D010098	none
Oxycodone	noroxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	noroxycodone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	noroxycodone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	noroxycodone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	noroxycodone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	noroxycodone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	noroxycodone	55	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	noroxycodone	55	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	noroxycodone	54	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	noroxycodone	54	53	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	noroxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	noroxycodone	53	53	false	none	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	noroxycodone	52	53	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	noroxycodone	52	53	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		7804	none	D010098	none
Oxycodone	Oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	Oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	Oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
Oxycodone	Oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
Oxycodone	Oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	Oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	Oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	Oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	Oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	rifampin	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	54	55	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	54	55	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	36	38	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		7804	none	D010098	none
Oxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		7804	none	D010098	none
Oxycodone	oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		7804	none	D010098	none
Oxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		7804	none	D010098	none
Oxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
Oxycodone	oxymorphone	45	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  		7804	none	D010098	none
Oxycodone	oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	oxymorphone	45	46	false	none	Excretion  Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		7804	none	D010098	none
Oxycodone	oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	oxymorphone	48	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.  Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.  		7804	none	D010098	none
Oxycodone	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	54	56	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	54	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	54	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	52	54	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	52	54	false	none	Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		7804	none	D010098	none
Oxycodone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	Oxycodone hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	2	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	2	3	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	2	4	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	3	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	3	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	3	4	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	3	5	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	5	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	5	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	5	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	6	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	6	8	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	7	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	7	8	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	7	9	false	none	Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	8	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	8	9	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	9	8	false	none	Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	9	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	9	11	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	11	9	false	none	Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla.  The frequency and severity of emesis gradually diminishes with time.  Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	11	11	false	none	Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	15	16	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	15	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	16	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	16	15	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	18	16	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	27	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	26	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	28	26	false	none	12.3 Pharmacokinetics  The activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone.  The oral bioavailability of oxycodone is 60% to 87%.  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	35	37	false	none	Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%.  Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	36	37	false	none	Oxycodone has been found in breast milk.  Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
Oxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		D010098	D010098
Oxycodone	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone	histamine	18	17	false	none	Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		7804	5333	D010098	D006632
Oxycodone	histamine	18	17	false	none	Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension.  		7804	5333	D010098	D006632
gh	prolactin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	1426890	none	D011388
gh	prolactin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	1426890	none	D011388
gh	noroxycodone	51	53	false	none	Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance <60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function.  Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment.  Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  		none	none	none	none
gh	noroxycodone	42	40	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
gh	noroxycodone	42	41	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
gh	lh	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	none	none	none
gh	Oxymorphone	42	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
gh	Oxymorphone	42	43	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
gh	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5492	none	D006854
gh	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5492	none	D006854
gh	oxymorphone	42	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
gh	oxymorphone	42	43	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
gh	growth hormone	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	none	none	D013006
gh	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	6383	none	6383
gh	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	6383	none	6383
gh	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	376	none	D000324
gh	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	376	none	D000324
gh	Oxycodone hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action  Oxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses.  In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	2	false	none	In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.  Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	3	false	none	Effects on the Central Nervous System (CNS)  The principal therapeutic action of oxycodone hydrochloride is analgesia.  Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	4	5	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	4	false	none	Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.  In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	5	false	none	In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers.  Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	8	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		none	7804	none	D010098
gh	Oxycodone hydrochloride	6	8	false	none	Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla.  Oxycodone causes miosis, even in total darkness.  Effects on the Gastrointestinal Tract And Other Smooth Muscle  Gastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride.  		none	7804	none	D010098
gh	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	none	D007328
gh	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	none	D007328
prolactin	lh	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	none	D011388	none
prolactin	lh	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	none	D011388	none
prolactin	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	5492	D011388	D006854
prolactin	cortisol	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	5492	D011388	D006854
prolactin	growth hormone	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	none	D011388	D013006
prolactin	growth hormone	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	none	D011388	D013006
prolactin	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	6383	D011388	6383
prolactin	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	6383	D011388	6383
prolactin	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	376	D011388	D000324
prolactin	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	376	D011388	D000324
prolactin	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	5856	D011388	D007328
prolactin	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		1426890	5856	D011388	D007328
noroxycodone	Oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	Oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	Oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	Oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
noroxycodone	Oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
noroxycodone	Oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
noroxycodone	Oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
noroxycodone	Oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
noroxycodone	Oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
noroxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	none	none	none
noroxycodone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
noroxycodone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
noroxycodone	oxymorphone	40	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs.  The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  		none	none	none	none
noroxycodone	oxymorphone	40	42	false	none	The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
noroxycodone	oxymorphone	41	42	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
noroxycodone	oxymorphone	41	43	false	none	Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
noroxycodone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
noroxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  		none	none	none	none
noroxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
noroxycodone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
noroxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
noroxycodone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
lh	cortisol	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	5492	none	D006854
lh	cortisol	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	5492	none	D006854
lh	growth hormone	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	none	none	D013006
lh	luteinizing hormone	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	6383	none	6383
lh	luteinizing hormone	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	6383	none	6383
lh	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	376	none	D000324
lh	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		none	376	none	D000324
lh	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	none	D007328
lh	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	none	D007328
Oxymorphone	p450	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
Oxymorphone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
Oxymorphone	oxymorphone	38	38	false	none	CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Oxymorphone	oxymorphone	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Oxymorphone	oxymorphone	37	38	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	none	none	none
Oxymorphone	oxymorphone	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	none	none	none
Oxymorphone	oxymorphone	42	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  		none	none	none	none
Oxymorphone	oxymorphone	42	43	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
Oxymorphone	oxymorphone	43	42	false	none	Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
Oxymorphone	oxymorphone	43	43	false	none	The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  		none	none	none	none
Oxymorphone	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
Oxymorphone	oxymorphone	46	46	false	none	The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone <14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  		none	none	none	none
Oxymorphone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
Oxymorphone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Oxymorphone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
Oxymorphone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
Oxymorphone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
p450	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
p450	oxymorphone	56	56	false	none	CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
p450	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
cortisol	growth hormone	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		5492	none	D006854	D013006
cortisol	growth hormone	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		5492	none	D006854	D013006
cortisol	luteinizing hormone	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		5492	6383	D006854	6383
cortisol	luteinizing hormone	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		5492	6383	D006854	6383
cortisol	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		5492	376	D006854	D000324
cortisol	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		5492	376	D006854	D000324
cortisol	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		5492	5856	D006854	D007328
cortisol	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		5492	5856	D006854	D007328
rifampin	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
rifampin	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  		none	none	none	none
oxymorphone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	none	none	none
oxymorphone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
oxymorphone	Oxycodone hydrochloride	38	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone.  		none	7804	none	D010098
oxymorphone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
oxymorphone	Oxycodone hydrochloride	37	37	false	none	Metabolism  Oxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated.  		none	7804	none	D010098
growth hormone	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	6383	D013006	6383
growth hormone	luteinizing hormone	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	6383	D013006	6383
growth hormone	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	376	D013006	D000324
growth hormone	ACTH	22	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	376	D013006	D000324
growth hormone	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	D013006	D007328
growth hormone	insulin	22	22	false	none	They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		none	5856	D013006	D007328
luteinizing hormone	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		6383	376	6383	D000324
luteinizing hormone	ACTH	21	21	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  		6383	376	6383	D000324
luteinizing hormone	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		6383	5856	6383	D007328
luteinizing hormone	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		6383	5856	6383	D007328
ACTH	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		376	5856	D000324	D007328
ACTH	insulin	21	22	false	none	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  		376	5856	D000324	D007328
Oxycodone hydrochloride	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone hydrochloride	histamine	16	17	false	none	Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone hydrochloride	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
Oxycodone hydrochloride	histamine	15	17	false	none	Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase.  Effects on the Cardiovascular System  In therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes.  Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.  		7804	5333	D010098	D006632
